Influence of Serum Biomarkers in the Diagnostic, Prognostic and Therapeutic Management of Patients with Heart Failure

¹Division of Cardiovascular Medicine, Clinic Hospital, Asuncion National University (UNA), San Lorenzo, Paraguay.
²Department of Health Sciences Investigation. Sanatorio Metropolitano. Fernando de la Mora. Paraguay.

Corresponding Author: Osmar Antonio Centurión, Division of Cardiovascular Medicine, Clinic Hospital, Asuncion National University (UNA), San Lorenzo, Paraguay, Tel: + (595) 971 354444; E-Mail: [email protected]

Received Date:  21 Sep 2018  
Accepted Date:  24 Sep 2018  
Published Date: 25 Sep 2018

Copyright © 2018 Centurión OA

Citation: Centurión OA, Chávez-Alfonso C, García LB and Torales JM. (2018). Influence of Serum Biomarkers in the Diagnostic, Prognostic and Therapeutic Management of Patients with Heart Failure Mathews J Cardiol. 3(1): 017.

ABSTRACT

Heart failure (HF) is a clinical syndrome caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intra-cardiac pressures at rest or during stress. HF continues to be a significant cause of morbidity and mortality worldwide, and over a half of patients with acute HF admitted to the hospital have a history of coronary heart disease. In addition, a substantial proportion of hospitalized patients with coronary heart disease develop acute HF during the hospital stay, and have a worse prognosis in those patients who develop acute HF at the initial presentation. Given the diversity of clinical presentations, several different physio-pathological mechanisms along with triggering factors of circulatory decompensation are involved. The improvement in clinical assessment of HF patients by the utilization of noninvasive and biologically meaningful serum biomarkers has considerably paved the way on HF diagnostic and therapeutic management. Indeed, serum biomarkers allow safe, objective, and biologically relevant insight that complements clinical findings of HF patients. They are useful for determining diagnosis, prognosis, or therapy decision making. There are different biomarkers that can be measured during the evolution of HF, as well as, several pathways involved in HF progression. Therefore, it may be rational to utilize a multi-biomarker measurement approach to individualize the diagnosis, prognosis and therapeutic management in patients with heart failure.

KEYWORDS

Heart failure; Serum biomarkers; Natriuretic peptides; Galectin; MicroRNA.